E&C Kicks Off the Road to PDUFA VIII: The House Energy and Commerce Health Subcommittee holds a hearing Wednesday, July 15 at 10:15 a.m. titled Maintaining America’s Leadership in Biomedical Innovation: FDA’s Role in Advancing U.S. Drug Development. The session will examine how to streamline FDA’s current drug development and clinical trial requirements, and E&C Chairman Guthrie and E&C Health Subcommittee Griffith framed it explicitly as table-setting for next year’s reauthorization of FDA’s user fee programs. The user fee agreements set the terms of engagement with FDA for the next five years, including review timelines, meeting access, and the resources behind the review divisions our companies interact with daily. We’ll be listening for how members approach clinical trial modernization, review efficiency, and agency stability, and we’ll be engaging throughout the reauthorization process to ensure the Massachusetts perspective is at the table.
House China Committee Turns to Research Security: That same morning, the House Select Committee on China holds a hearing titled Protecting American Innovation: The Federal Research Security Enterprise, featuring witnesses from the Department of Energy, NIH, and NSF. Research security is a legitimate priority, but the details matter enormously for a state whose innovation economy is anchored by research universities and academic medical centers, so we’ll be watching closely and share a readout next week.
MassBio Supports SEC Semiannual Reporting Proposal: Earlier this week, MassBio filed a comment letter supporting the SEC’s proposal to allow public companies to file semiannual reports on a new Form 10-S in place of quarterly 10-Qs. Quarterly reporting is poorly matched to the realities of pre-revenue biotechs, whose value is driven by clinical and regulatory milestones rather than quarterly financials, and whose material developments already reach investors promptly through Form 8-K, press releases, and Regulation FD. The compliance savings would flow directly back into R&D, and because the proposal is optional, companies whose investors prefer quarterly cadence can keep it.
